FRIDAY, May 19, 2023 (HealthDay News) — A new brain bank is accepting future donations from living athletes, in an effort to perform long-term research into the effects of sports-related concussion. The National Sports Brain Bank (NSBB) at the University of Pittsburgh will track the health of living participants onContinue Reading

MONDAY, May 15, 2023 — Researchers have discovered a genetic mutation that should actively protect people from Alzheimer’s, thanks to a man belonging to a Colombian family known to be susceptible to the degenerative brain disease. Based on his family’s genetics, this unnamed patient should have started showing signs ofContinue Reading

THURSDAY, May 11, 2023 (HealthDay News) — A medication to treat agitation in Alzheimer’s patients now has approval from the U.S. Food and Drug Administration. The FDA gave supplemental approval to Otsuka Pharmaceutical Company Ltd., and Lundbeck Inc. for Rexulti (brexpiprazole) oral tablets on Thursday. Rexulti is the first FDA-approvedContinue Reading

THURSDAY, May 11, 2023 (HealthDay News) — Poor sleep brought on by sleep apnea may ultimately undermine the brain health of older men and women, new research suggests. The concern stems from a new brain scan investigation that involved 140 sleep apnea patients. “Sleep apnea is a medical condition inContinue Reading

WEDNESDAY, May 10, 2023 (HealthDay News) — Researchers have isolated for the first time a free-floating form of amyloid beta that appears to be a key driver of Alzheimer’s disease. Further, they argue that a newly approved Alzheimer’s drug — lecanemab (Leqembi) — directly targets these small, complex chains ofContinue Reading

FRIDAY, May 5, 2023 (HealthDay News) — Getting good sleep is an important part of wellness for many reasons, but new research suggests deep sleep may even guard against memory loss linked to Alzheimer’s. While disrupted sleep has been linked with accumulating beta-amyloid plaques in the brain faster, scientists foundContinue Reading

WEDNESDAY, May 3, 2023 (HealthDay News) — Another experimental drug meant for Alzheimer’s disease looks so promising that drugmaker Eli Lilly plans to ask the U.S. Food and Drug Administration for full approval by the end of June. Known as donanemab, the medication clears amyloid plaque from the brain. InContinue Reading